The 26th International AIDS Conference (AIDS 2026)

Rio de Janeiro, Brazil 26 July 2026 - 31 July 2026

Two-drug noninferior to three-drug ART as initial HIV treatment

In individuals with untreated HIV-1 infection, the two-drug dolutegravir/lamivudine (DTG/3TC) antiretroviral therapy (ART) regimen has similar efficacy as the three-drug bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen, according to the phase IIIb VOGUE study.

Two-drug noninferior to three-drug ART as initial HIV treatment

18 hours ago

Injectable HIV Tx trumps daily pill in virally suppressed adolescents

04 Sep 2026 by

The week-96 LATA trial results demonstrate the superiority of long-acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) to tenofovir/lamivudine/dolutegravir (TLD) for maintaining virologic suppression in adolescents with HIV in sub-Saharan Africa.

Injectable HIV Tx trumps daily pill in virally suppressed adolescents

04 Sep 2026

Lenacapavir continues to serve its PURPOSE in OLE study

03 Sep 2026 by

Twice-yearly subcutaneous lenacapavir continues to show high efficacy and is well tolerated among cisgender men and gender-diverse individuals in the open-label extension (OLE) of the PURPOSE 2 trial.

Lenacapavir continues to serve its PURPOSE in OLE study

03 Sep 2026

Doravirine-based ART matches dolutegravir-based regimen in efficacy with less weight gain

01 Sep 2026 by

Among treatment-naïve adults with HIV who are initiating antiretroviral therapy (ART), a regimen containing doravirine, lamivudine, and tenofovir disoproxil fumarate (DOR/3TC/TDF) is as good as the dolutegravir, emtricitabine, and tenofovir alafenamide (DTG/FTC/TAF) regimen in terms of viral suppression but is associated with less weight gain, according to the open-label, head-to-head OPTI-DOR study conducted in South Africa.

Doravirine-based ART matches dolutegravir-based regimen in efficacy with less weight gain

01 Sep 2026